Prophylactic irradiation of pelvic lymph nodes in patients with high risk of prostate cancer progression: a review

«Radiation and Risk», 2021, vol. 30, No. 4, pp.94-107

DOI: 10.21870/0131-3878-2021-30-4-94-107

Authors

Kireeva T.A. – Junior Researcher. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: 89533356886; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Gumenetskaya Y.V. – Head of Dep., MD
Biryukov V.A. – Sen. Researcher, C. Sc. Med.
Obukhov A.A. – Sen. Researcher, C. Sc. Med.
Makarova K.S. – Radiologist
Strikanova I.A. – Radiologist
Dzhabrailova S.O. – Radiologist. A. Tsyb MRRC.
A. Tsyb MRRC, Obninsk

Abstract

One way to enhance the effectiveness of treatment for high-risk prostate cancer is to use combined hormonal/radiation therapy. The effectiveness of this approach has already been demonstrated and confirmed. The study results show that application of the hormonal therapy potentiates the total radiation effect and makes 5-year local control is more effective compared with the control achieved after application of EBRT modality. At the same time, if high dose radiation therapy is applied or large volume to be exposed to radiation, in both cases there is increased risk of radiation-induced side effects development. The radiation-related complications affect patients’ quality of life significantly. A natural question arises in such a case, whether inclusion of lesion free pelvic lymph nodes (N0) in patients with high risk of prostate cancer progression in the area of radiation exposure is necessary, if no data on their lesion (N0) are available and thus to increase the irradiated volume significantly. The considered published studies devoted to the problem were considered, the most part of the studies a retrospective, results of some studies contradicted conclusions. This does not allow us to find definitive answer to the “natural” question. Until now, it is also unknown what criteria are to be used for deciding whether radiotherapy to the area of regional metastasis zones is necessary. In this connection, it would be reasonable to conduct a prospective randomized study, its results will possibly allow us to assess the need for prophylactic irradiation of the pelvic lymph nodes during combined modality radiotherapy for high risk prostate cancer patients.

Key words
prostate cancer, high risk, prophylactic irradiation lymph nodes, dose escalation, radiotoxicity, the radiation-related complications.

References

1. The status of cancer care for the population in Russia in 2018. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow, Р. Hertsen MORI – branch of the NMRRC of the Ministry of Health of the Russian Federation, 2019. p. 18. (In Russian).

2. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow, Р. Hertsen MORI – branch of the NMRRC of the Ministry of Health of the Russian Federation, Moscow, 2019. pp. 4-6. (In Russian).

3. Popkov V.M., Kim T.D., Ponukalin A.N. Diagnosis and combined treatment of patients with locally advanced prostate cancer (review). Saratovskiy nauchno-meditsinskiy zhurnal – Saratov Journal of Medical Scientific Research, 2015, vol. 11, no. 3, pp. 317-322. (In Russian).

4. D’Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., Tomaszewski J.E., Renshaw A.A., Kaplan I, Beard C.J., Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J. Am. Med. Assoc. (JAMA), 1998, vol. 280, no. 11, pp. 969-974.

5. NCCN Guidelines Version 2.2021. Prostate cancer, version 2.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed 12.12.2020).

6. Veliev E.I., Okhrits V.E., Obeid A.Kh. Prognostic factors of prostate cancer before and after radical prostatectomy. Onkourologiya – Cancer Urology, 2011, vol. 7, no. 2, pp. 52-55. (In Russian).

7. Shikanov S., Marchetti P., Desai V., Razmaria A., Antic T., Al-Ahmadie H., Zagaja G., Eggener S., Brendler C., Shalhav A. Short (1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int., 2013, vol. 111, no. 4, pp. 559-563.

8. Gerber G.S., Thisted R.A., Chodak G.W., Schroder F.H., Frohmuller H.G.W., Scardino P.T., Paulson D.F., Middleton A.W., Rukstalis D.B., Smith J.A., Ohori M., Theiss M., Schellhammer P.F. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur. Urol., 1997, vol. 32, no. 4, pp. 385-390.

9. Lerner S.E., Blute M.L., Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J. Urol., 1995, vol. 154, no. 4, pp. 1447-1452.

10. Boccon-Gibod L., Bertaccini A., Bono A.V., Sarmah B.D., Höltl W., Mottet N., Tunn U., Zamboglou N. Management of locally advanced prostate cancer: a European consensus. Int. J. Clin. Pract., 2003, vol. 57, no. 3, pp. 187-194.

11. Karyakin O.B. Standards in the treatment of various stages of prostate cancer. Prakticheskaya onkologiya – Practical Oncology, 2001, vol. 6, no. 2, pp. 24-27. (In Russian).

12. Knipper S., Palumbo C., Pecoraro A., Rosiello G., Tian Z., Briganti A., Kevin C. Z., Saad F., Tilki D., Graefen M., Pierre I., Karakiewicz P.I. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: a population-based analysis. Urol. Oncol., 2020, vol. 38, no. 3, pp. 9-14.

13. Heemsbergen W.D., Al-Mamgani A., Slot A., Dielwart M.F.H., Lebesque J.V. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother. Oncol., 2014, vol. 110, no. 1, pp. 104-109.

14. Michalski J.M, Moughan J., Purdy J., Bosch W., Bruner D.W., Bahary J.P., Lau H., Duclos M., Parliament M., Morton G., Hamstra D., Seider M., Lock M.I., Patel M., Gay H., Vigneault E., Winter K., Sandler H. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol., 2018, vol. 4, no. 6, p. e180039.

15. Dearnaley D.P., Jovic G., Syndikus I., Khoo V., Cowan R.A., Graham J.D., Aird E.G., Bottomley D., Huddart R.A., Jose C.C., Matthews J.H., Millar J.L., Murphy C., Russell J.M., Scrase C.D., Parmar M.K., Sydes M.R. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol., 2014, vol. 15, no. 4, pp. 464-473.

16. Viani G. A., Stefano E.J., Afonso S.L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int. J. Radiat. Oncol. Biol. Phys., 2009, vol. 74, no. 5, pp. 1405-1418.

17. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., van Putten W.L.J., Slot A., Dielwart M.F.H., Bonfrer J.M.G., Incrocci L., Lebesque J.V. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol., 2006, vol. 24, no. 13, pp. 1990-1996.

18. Chennupati S.K., Pelizzari C.A., Kunnavakkam R., Liauw S.L. Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med., 2014, vol. 3, no. 4, pp. 954-961.

19. Spratt D.E., Pei X., Yamada J., Kollmeier M.A., Cox B., Zelefsky M.J. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2013, vol. 85, no. 3, pp. 686-692.

20. Vora S.A., Wong W.W., Schild S.E., Ezzell G.A., Andrews P.E., Ferrigni R.G., Swanson S.K. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J. Urol., 2013, vol. 190, no. 2, pp. 521-526.

21. Sveistrup J., Rosenschöld P., Deasy J.O., Oh J., Pommer T., Petersen P., Engelholm S. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat. Oncol., 2014, vol. 9, p. 44.

22. Bolla M., Collette L., Van Tienhoven G., Warde P., Dubois J.B., Mirimanoff R.O.M., Storme G., Bernier J., Kuten A., Piérart M. Ten years results of long term adjuvant androgen deprivation with Goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study. Int. J. Radiat. Oncol. Biol. Phys., 2008, vol. 72, no. 1, pp. S30-S31.

23. Hanks G.E., Pajak T.F., Porter A., Grignon D., Brereton H., Venkatesan V., Horwitz E.M., Lawton C., Rosenthal S.A., Sandler H.M., Shipley W.U. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol., 2003, vol. 21, no. 21, pp. 3972-3978.

24. Morozov S.P., Bezrukov E.A. Tomographic methods in prostate cancer evaluation. Rossiyskiy elektronnyy zhurnal luchevoy diagnostiki – Russian Electronic Journal of Radiology, 2011, vol. 1, no 4. pp. 18-26. (In Russian).

25. Storey M. R., Pollack A., Zagars G., Smith L., Antolak J., Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 2000, vol. 48, no. 3, pp. 635-642.

26. Murthy V., Maitre P., Bhatia J., Kannan S., Krishnatry R., Prakash G., Bakshi G., Pal M., Menon S., Mahantshetty U. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial. Radiother. Oncol., 2020, vol. 145, pp. 71-80.

27. Deville C., Both S., Hwang W.T., Tochner Z., Vapiwala N. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2010, vol. 78, no. 3, pp. 763-772.

28. Roach M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., Rotman M., Jones C., Asbell S.O., Valicenti R.K., Han S., Thomas C.R., Shipley W.S. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol., 2003, vol. 21, no. 10, pp. 1904-1911.

29. Roach M., DeSilvio M., Valicenti R., Grignon D., Asbell S.O., Lawton C., Thomas C.R., Shipley W.U. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int. J. Radiat. Oncol. Biol. Phys., 2006, vol. 66, no. 3, pp. 647-653.

30. Roach M., Moughan J., Lawton C.A.F., Dicker A.P., Zeitzer K.L., Gore E.M., Kwok Y., Seider M.J., Hsu I-C., Hartford A.C., Horwitz E.M., Yamoah K., Jones C.U., Michalski J.M., Lee W.R., Pisansky T.M., Rabinovitch R., Rotman M., Pryzant R.M., Kim H.E., Thomas C.R.J., Shipley W.U., Sandler H.M. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol., 2018, vol. 19, no. 11, pp. 1504-1515.

31. Lawton C.A., DeSilvio M., Roach M., Uhl V., Kirsch R., Seider M., Rotman M., Jones C., Absel S., Valicenti R., Hahn S., Thoma C.R. An update of the Phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys., 2007, vol. 69, no. 3, pp. 646-655.

32. Roach M., Marquez C., You H.-S., Narayan P., Coleman L., Nseyo U.O., Navvab Z., Carroll P.R. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1994, vol. 28, no. 1, pp. 33-37.

33. Aizer A.A., Yu J.B., McKeon A.M., Decker R.H., Colberg J.W., Peschel R.E. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys., 2009, vol. 75, no. 5, pp. 1344-1349.

34. Seaward S.A., Weinberg V., Lewis P., Leigh B., Phillips T. L., Roach M. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1998, vol. 42, no. 5, pp. 1055-1062.

35. Seaward S.A., Weinberg V., Lewis P., Leigh B., Phillips T.L., Roach M. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J. Sci. Am., 1998, vol. 4, no. 6, pp. 370-377.

36. Partin A.W., Yoo J., Carter H.B., Pearson J.D., Chan D.W., Epstein J.I., Walsh P.C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 1993, vol. 150, no. 1, pp. 110-114.

37. Pan C., Ki K., Taylor J.M., McLaughlin P., Sandler H. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2002, vol. 53, no. 5. pp. 1139-1145.

38. Zagars G.K., von Eschenbach A.C., Johnson D.E., Oswald M.J. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer, 1987, vol. 60, no. 7, pp. 1489-1499.

39. Pommier P., Chabaud S., Lagrange J.-L., Richaud P., Le Pris E., Wagner J.-P., Azria D., Beckendorf V., Suchaud J-P., Bernier V., Perol D., Carrie C. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int. J. Radiat. Oncol. Biol. Phys., 2016, vol. 96, no. 4, pp. 759-769.

40. Al-Mamgani A., Lebesque J.V., Heemsbergen W.D., Tans L., Kirkels W. J., Levendag P.C., Incrocci L. Controversies in the treatment of high-risk prostate cancer what is the optimal combination of hormonal therapy and radiotherapy: a review of literature. Prostate, 2010, vol. 70, no. 7, pp. 701-709.

41. Kanaev S.V., Novikov S.N., Gafton G.I., Novikov R.V. The combination of external radiation therapy with high dose rate brachytherapy boost for prostate cancer: a comparative characteristic of two fraction modes. Sibirskiy onkologicheskiy zhurnal – Siberian Journal of Oncology, 2020, vol. 19, no. 1, pp. 40-49. (In Russian).

42. Spratt D.E., Soni P.D., McLaughlin P.W., Merrick G.S., Stock R.G., Blasko J.C., Zelefsky M.J. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy, 2017, vol. 16, no. 1, pp. 1-12.

43. Tharmalingam H., Tsang Y., Choudhury A., Alonz, R., Wylie J., Ahmed I., Henry A., Heath C., Hoskin P.J. External beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int. J. Radiat. Oncol. Biol. Phys., 2019, vol. 106, no. 3, pp. 525-533.

44. Sandler K.A., Cook R.R., Ciezki J.P., Ross A.E., Pomerantz M.M., Nguyen P.L., Shaikh T., Tran P.T., Stock R.G., Merrick G.S., Demanes D.J., Spratt D.E., Abu-Isa E.I., Wedde T.B., Lilleby W., Krauss D.J., Shaw G.K., Alam R., Reddy C.A., Song D.Y., Klein E.A., Stephenson A.J., Tosoian J.J., Hegde J.V., Yoo S.M., Fiano R., D'Amico A.V., Nickols N.G., Aronson W.J., Sadeghi A., Greco S.C., Deville C. Jr., McNutt T., DeWeese T.L., Reiter R.E., Said J.W., Steinberg M.L., Horwitz E.M., Kupelian P.A., King C.R., Kishan A.U. Prostate-only versus whole-pelvis radiation with or without a brachytherapy boost for Gleason grade group 5 prostate cancer: a retrospective analysis. Eur. Urol., 2020, vol. 77, no. 1, pp. 3-10.

Full-text article (in Russian)